XENE Stock Summary and Trading Ideas (Xenon Pharmaceuticals - Common Shares | NASDAQ:XENE)

Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

Xenon Pharmaceuticals - Common Shares trades on the NASDAQ stock market under the symbol XENE.

As of September 4, 2026, XENE stock price declined to $59.75 with 438,435 million shares trading.

XENE has a beta of 0.26, meaning it tends to be less sensitive to market movements. XENE has a correlation of 0.01 to the broad based SPY ETF.

XENE has a market cap of $5.79 billion. This is considered a Mid Cap stock.

Last quarter Xenon Pharmaceuticals - Common Shares reported $0 in Revenue and -$1.11 earnings per share. This fell short of revenue expectation by $-937,500 and exceeded earnings estimates by $.05.

In the last 3 years, XENE traded as high as $72.66 and as low as $26.74.

The top ETF exchange traded funds that XENE belongs to (by Net Assets): IWO, VTWO, TCAF, SPDW, FESM.

XENE has outperformed the market in the last year with a return of +54.6%, while the SPY ETF gained +19.8%. In the last 3 month period, XENE beat the market returning +12.8%, while SPY returned +2.0%. However, in the most recent 2 weeks XENE has underperformed the stock market by returning -1.7%, while SPY returned +0.6%.

XENE support price is $59.01 and resistance is $61.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XENE shares will trade within this expected range on the day.